Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coley Seeks HCV Partner For Actilon

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm suspends independent development of the hepatitis C agent in hopes of finding a partner with resources and expertise to share the risk.
Advertisement

Related Content

Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy
Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy
Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End
Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End
Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer
Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS065058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel